Markets:

Overview

News

Currencies

International

Treasuries

Novartis AG Common Stock (NY:NVS)

149.50 +1.42 (+0.96%)

Streaming Delayed Price Updated: 1:01 PM EDT, May 18, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2

...

19 20 21 22 23 24 25 26 27

...

56 57 Next >

Week In Review: 2024 Kicks Off With Three Deals Worth A Total Of $4 Billion ↗

January 07, 2024

Suzhou Ribo Life Science formed a collaboration with Boehringer Ingelheim in a deal that could be worth up to $2 billion. Additionally, Allorion Therapeutics has out-licensed global rights (ex-China)...

Via Talk Markets

(NVS) - Analyzing Novartis's Short Interest ↗

January 05, 2024

Via Benzinga

Novartis AG (NYSE: NVS) Records 52-Week High Friday Morning

January 05, 2024

Via Investor Brand Network

Voyager Therapeutics Stock Tanked After-Hours - Here's Why ↗

January 04, 2024

Voyager Therapeutics, Inc. (NASDAQ: VYGR) shares are trading lower in Thursday's after-hours session after announcing a proposed public offering

Via Benzinga

Big Players' Recent Trades in NVS Options ↗

January 04, 2024

Via Benzinga

VYGR Stock Alert: The $1.2 Billion Reason Voyager Therapeutics Is Up Today ↗

January 02, 2024

VYGR stock is in focus as analysts expect more pharma deals in 2024, although some think these deals will be sunk by the Biden administration.

Via InvestorPlace

(NVS) - Analyzing Novartis's Short Interest ↗

December 20, 2023

Via Benzinga

(NVS) - Analyzing Novartis's Short Interest ↗

December 01, 2023

Via Benzinga

Why Is Gene Therapy Focused Voyager Therapeutics Stock Soaring Today? ↗

January 02, 2024

Voyager Therapeutics Inc (NASDAQ: VYGR) announced a strategic collaboration and capsid license agreement with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE: NVS), to advance pot

Via Benzinga

Novartis Sweetens Its Deal With Voyager, And Voyager Stock — Up 25% — Flashes A Bullish Sign ↗

January 02, 2024

The company inked an expanded collaboration deal with Novartis to test out gene therapies.

Via Investor's Business Daily

2 gene-editing stocks reshaping hereditary disease treatments

January 02, 2024

Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal

Via MarketBeat

Why Is Neurology Focused Cingulate Stock Trading Higher Today? ↗

December 28, 2023

On Tuesday, Cingulate Inc (NASDAQ: CING) received FDA guidance f

Via Benzinga

Why Is Cytokinetics (CYTK) Stock Up 70% Today? ↗

December 27, 2023

With Cytokinetics hitting a homerun with its heart failure drug, CYTK stock skyrocketed in part due to takeover interest.

Via InvestorPlace

Bristol Myers Squibb Takes On Novartis, Eli Lilly With RayzeBio $4B Deal In Radiopharmaceuticals ↗

December 26, 2023

Bristol Myers Squibb & Co (NYSE: BMY) has agreed to acquire RayzeBio Inc (NASDAQ: RYZB) for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of <

Via Benzinga

These 3 Big Pharma Stocks Are Making Big Plays With AI ↗

December 22, 2023

Opportunity is in the air with AI, and these pharma giants are seizing the moment.

Via The Motley Fool

Topics Artificial Intelligence

Calliditas Therapeutics Scores Complete FDA Approval, Broader Label For Lead Kidney Disease Drug ↗

December 21, 2023

The FDA approved Calliditas Therapeutics AB's (NASDAQ: CALT) Tarpeyo (budesonide) delayed-release capsules to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy...

Via Benzinga

Fusion's Pharma's Targeted Cancer Therapy Potential Gets This Analyst Bullish, Sees 100% Upside ↗

December 20, 2023

RBC Capital Markets initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN), saying the radiopharmaceutical industry is a burgeoning area in therapeutics following the green light for Novartis...

Via Benzinga

Lantheus Downgraded Due To Reliance On PNT2002; Analyst Cites Comparable Profile To Novartis' Drug ↗

December 19, 2023

Monday, Lantheus Holdings Inc (NASDAQ: LNTH) and POINT Biopharma Global Inc (NASDAQ: PNT) reported topline data from pivotal Phase 3 SPLASH trial of 177Lu-PNT2002 in metastatic c

Via Benzinga

Are November’s 3 Biggest Stock Losers Worth Snapping Up Now? ↗

December 17, 2023

The market was like an iceberg with only a few winners showing but that means there are a lot of the biggest stock losers worth getting now.

Via InvestorPlace

FDA Approves Merck's Drug Belzutifan For Type Of Advanced Kidney Cancer In Pretreated Cancer Patients ↗

December 15, 2023

The FDA approved Merck & Co Inc's (NYSE: MRK) Welireg (belzutifan), an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, for adult patients with advanced renal cell carcinoma (RCC) following a...

Via Benzinga

Novartis' Newly FDA-Approved Rare Blood Disorder Drug Aces Phase 3 Study In Ultra Rare Kidney Failure Disease ↗

December 11, 2023

Novartis AG (NYSE: NVS) announced

Via Benzinga

This 1 Emerging Risk Could Be a Problem for These 3 Big Pharma Stocks ↗

December 10, 2023

Regulators are already on the case, and their findings will have financial impacts.

Via The Motley Fool

A Comprehensive Study Exploring Breast Cancer Treatment Market : Key Players Gilead Sciences, Astellas, Celgene

December 07, 2023

Get an extensive Breast Cancer Treatment Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry.

Via SBWire

Zoetis Stock A Good Companion For Your Portfolio? Shares Rising ↗

December 07, 2023

Reflecting strong fundamentals, Zoetis stock boasts a best-possible A SMR Rating (sales+profit margins+return on equity) on an A-to-E scale.

Via Investor's Business Daily

Novartis' Rare Blood Disorder Therapy Scores FDA Approval ↗

December 06, 2023

The FDA approved Novartis AG's (NYSE

Via Benzinga

Allergy Treatment Market Know Faster Growing Segments Now: Akorn, Pfizer, Novartis, Mylan N.V ↗

November 30, 2023

Global Allergy Treatment Market Breakdown by Application (Hospitals, Specialty Clinics, Homecare, Others) by Type (Eye Allergy, Food Allergy, Skin Allergy, Asthma, Rhinitis, Others) by Treatment...

Via SBWire

Anti-Inflammatory Drugs Market Boosting the Growth Worldwide 2030

November 29, 2023

Get Anti-inflammatory Drugs Market analysis, key vendors & competitive scenario of the market prepared using market research tools such as Porter’s five forces and SWOT analysis.

Via SBWire

Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies ↗

November 29, 2023

Tuesday, the FDA said it received reports of patients developing T-cell malig

Via Benzinga

3 Healthcare Stocks to Pick Up Before the Year-End Rally ↗

November 28, 2023

Explore the potential of healthcare stocks as the U.S. charges ahead with $4.3 trillion in healthcare spending

Via InvestorPlace

Novartis Outlines Pure-Play Strategy Progress After Generics Business Spin-Off ↗

November 28, 2023

Novartis AG (NYSE: NVS) has outlined the progress made in delivering its pure-play strategy, focused on four core therapeutic areas (Cardiovascular-Renal-Metabolic, Immunology, Neuroscience, Oncology),...

Via Benzinga

< Previous 1 2

...

19 20 21 22 23 24 25 26 27

...

56 57 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Novartis AG Common Stock (NY:NVS)

All News about Novartis AG Common Stock

Starting at $3.75/week.

Subscribe Today